![Rhonda Farnum](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rhonda Farnum
Technik-/Wissenschafts-/F&E-Leiter bei THERAVANCE BIOPHARMA, INC.
Vermögen: 3 Mio $ am 31.05.2024
Profil
Rhonda F.
Farnum is currently working as the Chief Business Officer & SVP-Medical Affairs at Theravance Biopharma, Inc. She started this position in 2021.
Previously, she worked at Onyx Pharmaceuticals, Inc. as the Head-Hematology Business Unit from 2014 to 2015.
Ms. Farnum completed her undergraduate degree at the University of Georgia.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
THERAVANCE BIOPHARMA INC
0,70% | 20.05.2024 | 339 965 ( 0,70% ) | 3 Mio $ | 31.05.2024 |
Aktive Positionen von Rhonda Farnum
Unternehmen | Position | Beginn |
---|---|---|
THERAVANCE BIOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Rhonda Farnum
Unternehmen | Position | Ende |
---|---|---|
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01.08.2015 |
Ausbildung von Rhonda Farnum
University of Georgia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
THERAVANCE BIOPHARMA, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |